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 10 
Abstract1 11 
Cancer is the second leading cause of mortality worldwide. The role of unresolved 12 
inflammation in cancer progression and metastasis is well established. Platelet-activating factor 13 
(PAF) is a key proinflammatory mediator in the initiation and progression of cancer. Evidence 14 
suggests that PAF is integral to the suppression of the immune system and the promotion of 15 
metastasis and tumor growth by altering the local angiogenic and cytokine networks. 16 
Interactions between PAF and its receptor may play a key role in various digestive, skin, and 17 
hormone-dependent cancers. Diet plays a critical role in the prevention of cancer and its 18 
treatment. Research indicates that the Mediterranean diet may reduce the incidence of several 19 
cancers in which dietary PAF inhibitors may in part play a role. Dietary PAF inhibitors such 20 
as polar lipids have demonstrated inhibitory effects against the physiological actions of PAF in 21 
                                                          
Abbreviations used: bFGF, basic fibroblast growth factor; CVD, cardiovascular diseases; COX, cyclooxygenases; 
ECM, extracellular matrix; ICAM, intercellular adhesion molecule; iNOS, inducible nitric oxide synthase; 
LPCAT, lysophosphatidylcholine acyltransferase; Lyso-PAF-AT, lyso-PAF-acetyltransferase; MMP, matrix 
metalloproteinase; PAF, platelet-activating factor; PAF-AH, platelet-activating factor-acetylhydrolase; PAF-
CPT, 1-alkyl-2-acetyl-sn-glycerol-cholinephosphotransferase; PAF-R, platelet-activating factor-receptor; PLA2, 
phospholipase A2; ROS, reactive oxygen species; VCAM, vascular cell adhesion molecule; VEGF, vascular 
endothelial growth factor. 
2 
 Nutrition, PAF, infammation, and cancer 
cancer and other chronic inflammatory conditions in vitro and in vivo. In addition, experimental 22 
models of radiotherapy and chemotherapy demonstrate that inhibition of PAF as adjuvant 23 
therapy may lead to more favorable outcomes. Although promising, there is limited evidence 24 
on the potential benefits of dietary PAF inhibitors on cancer prevention or treatment. Therefore, 25 
further extensive research is required to assess the effects of various dietary factors and PAF 26 
inhibitors and to elucidate the mechanisms that play a role in preventing cancer progression 27 
and metastasis at a molecular level.  28 
 29 
Keywords: nutrition; cancer, platelet-activating factor; inflammation; metastasis; 30 
angiogenesis; phospholipids; Mediterranean diet 31 
 32 
Introduction 33 
Cancer is a major public health concern worldwide. Although cancer death rates have 34 
decreased by 26% over the last two decades (1). Despite the decline, cancer remains a major 35 
cause of mortality. At least 1 in 2 people will develop a form of cancer within their lifetime in 36 
Ireland and the UK (2, 3). Cancer is not a single disease, but a collection of related diseases 37 
that act through similar but distinctive inflammatory pathways (4). It is typically considered a 38 
disease of old age, but with increasing longevity the incidence of most cancers is increasing 39 
(5). Known risk factors fail to fully explain the patterns of cancer development. Cancers arise 40 
from the accumulation of genetic mutations, either inherited or acquired that lead to 41 
dysregulation of cell division mechanisms that induce an uncontrolled proliferation. 42 
Proliferation is accompanied by low-grade inflammation mediated by several bioactive 43 
molecules such as platelet-activating factor (PAF) that play an integral role in the tumor 44 
microenvironment, particularly in hormone-dependent cancers (6, 7).  45 
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Cells generally regulate growth through decreasing their production rate or apoptosis, 46 
but uncontrolled growth can lead to tumor development and eventually symptomatic 47 
manifestations of cancer. Generally, a healthy immune system can eradicate neoplastic cells as 48 
soon as they appear. In cancer, the immune system fails to eradicate the cancer cells and 49 
proliferative growth occurs (5). Notably lifestyle, dietary, and environmental factors account 50 
for 95% of cancers, whereas 5% account for genetic factors (8, 9). Evidently, a large proportion 51 
of cancers are preventable by diet and lifestyle modification. However, the association between 52 
nutrition and cancer is bi-directional and exceedingly complicated (5). When cancerous cells 53 
develop, nutrition may exert significant effects on the growth and involution of a tumor (5). 54 
Several studies have reported evidence of an association between individual nutrients or foods 55 
and the risk of cancer; some foods have been known to induce or protect against mutagenic 56 
effects and improve the efficiency of the immune system (5).  57 
Inflammation is a protective physiological process of the innate immune system that 58 
occurs in response to tissue injury (10). Inflammation can be induced by both acute and chronic 59 
infections, physicochemical agents, diet, and lifestyle, which are causative and promotive of 60 
cancer (11). In some cancers, inflammatory conditions precede the development of 61 
malignancy; in others, oncogenic changes drive a tumor-promoting inflammatory milieu. 62 
Regardless of the origin of inflammation, both processes aid in the proliferation and survival 63 
of malignant cells, angiogenesis, and metastasis; subverts adaptive immunity, and alters 64 
response to hormones and chemotherapeutic agents (12). Epidemiological studies have 65 
demonstrated that systemic inflammation predisposes individuals to various types of cancer 66 
(13). It is estimated that underlying infections and inflammatory responses are linked to 15–67 
20% of all cancer-related deaths globally (14). Cancer development due to systemic 68 
inflammation is triggered by several factors such as autoimmune diseases (e.g. inflammatory 69 
bowel disease is associated with colon cancer (15)), microbial infections (e.g. Helicobacter 70 
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pylori is associated with gastric mucosal lymphoma and gastric cancer (16)), and inflammatory 71 
condition of unknown origin (e.g. prostatitis is associated with prostate cancer (17)). In 72 
addition, non-steroidal anti-inflammatory treatments decrease the incidence of cancers and 73 
mortality rates (18-21).  74 
PAF is a potent proinflammatory phospholipid mediator that is implicated in the 75 
development of cancer and other inflammatory conditions such as cardiovascular disease 76 
(CVD) (22). PAF plays a major role in in angiogenesis, thrombosis, carcinogenesis, and 77 
metastasis (10, 23). However, several dietary PAF-inhibitors, particularly found in foods in the 78 
Mediterranean diet have been identified that may inhibit the physiological actions of PAF (24), 79 
thus preventing the onset of inflammatory conditions such as cancer. In this review, we explore 80 
the potential role of dietary PAF inhibitors considering the most recent literature available.  81 
 82 
Current Status of Knowledge 83 
PAF structure, function, signaling, and metabolism  84 
Phospholipid mediators including prostaglandins and PAF play a significant role in 85 
several biological pathways of inflammatory diseases, including cardiovascular disease (CVD) 86 
and cancer (25, 26). The classical PAF structure (1-O-alkyl-2-acetyl-sn-glycero-3-87 
phosphocholine; Figure 1) is a prominent member of a family of molecules known as PAF-88 
like lipids (27) that are of semi-similar or non-similar structures with similar biological 89 
activities (22, 23, 28). PAF is synthesized by various cells including neutrophils, endothelial 90 
cells, platelets, macrophages, and monocytes (10). PAF is a potent pro-inflammatory mediator 91 
that affects various cells and pathological processes (10) and is implicated in angiogenesis, 92 
thrombosis, carcinogenesis, and metastasis (10, 23). PAF and its homologous lipids molecules 93 
are specific, structurally defined ligands that exclusively bind and induce their biological 94 
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activities through a unique seven-transmembrane G-protein-coupled receptor known as the 95 
PAF-receptor (PAF-R) with exceptionally high affinity (29-31). Engagement of the PAF-R by 96 
PAF or PAF-like lipids triggers an assortment of intracellular signaling cascades. This initiates 97 
biochemical mechanisms and functional responses of PAF-R bearing cells that then initiate or 98 
amplify inflammatory processes (32). The PAF-R is expressed on the surface of various 99 
mammalian cells, including leukocytes, platelets, macrophages, and endothelial cells (33, 34). 100 
PAF induced inflammatory processes are intensely involved in the initiation and progression 101 
of various cancers (22, 23, 34, 35). Although PAF-like lipids can bind to the PAF-R and initiate 102 
downstream effects, their effects are less severe than activation by PAF itself (36). 103 
PAF can activate cells in sub-picomolar concentrations (37), thus the physiological 104 
levels of PAF are tightly regulated by the PAF metabolic enzymes. Dysregulation of PAF 105 
metabolism leads to an increase in PAF levels that exacerbates the inflammatory response. PAF 106 
is inactivated and catabolized by the removal of the acetyl-group on the sn-2 position of the 107 
phospholipid molecules by PAF-specific acetylhydrolase (PAF-AH, EC 3.1.1.47) to form lyso-108 
PAF (38). Lyso-PAF lacks the activity of PAF and it is cytotoxic in nature. Lyso-PAF is then 109 
reconverted into PAF or other phospholipids by the introduction of an acetyl or acyl group to 110 
the sn-2 position; hence, the biological cycle of PAF is spontaneously regulated (39). The PAF-111 
AH enzymes are a class of enzymes that have the capacity to indirectly terminate PAF-induced 112 
signaling pathways by directly reducing either enzymatic or oxidative upregulation of 113 
increased PAF levels (23). Thus administration of recombinant PAF-AH has exhibited 114 
beneficial effects by downregulating PAF concentrations (33, 40, 41).  115 
 The primary role of PAF in physiology is to mediate cellular function and cell-cell 116 
interactions, which are critical in both physiologic and pathologic processes (42). The role of 117 
PAF is best-characterized by its involvement in the mediation of normal inflammatory 118 
responses and the regulation, blood circulation, blood pressure and regulation of coagulation 119 
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responses (22, 42). However, is also exerts signaling functions in glycogen degradation, 120 
reproduction, fetal implantation, exocrine gland function, lung maturation, initiation of 121 
parturition, and brain function (22). PAF is synthesized by many cells on demand in response 122 
to specific stimuli, including cytokines, endotoxins, Ca2+ ionophores, and PAF itself (25). The 123 
biosynthesis of PAF is accomplished by two distinctive enzymatic processes; the de novo and 124 
the remodeling pathways (43-45). The first biosynthetic pathway is the remodeling pathway, 125 
whereby phospholipase A2 (PLA2) converts the ether analogues of phosphatidylcholine to lyso-126 
PAF, which is then acetylated to PAF by isoforms of acetyl-CoA and lyso-PAF 127 
acetyltransferases (Lyso-PAF ATs, EC 2.3.1.67), notably LPCAT1 and LPCAT2 (46, 47). 128 
Evidence suggests that the production of PAF by LPCAT2 is activated under inflammatory 129 
conditions, whereas the role of LPCAT1 is still under investigation, since it is calcium 130 
independent and does not seem to engage in inflammatory processes (47).  131 
 The second PAF biosynthetic pathway is the de novo pathway, which initiates with the 132 
acylation of 1-O-alkyl-sn-glycero-3 phosphate by the 1-O-alkyl-sn-glycero-3 phosphate acetyl-133 
CoA acyltransferase, followed by the sequential actions of a phosphohydrolase and the specific 134 
activity of dithiothreitol-insensitive CDP-choline: 1-alkyl-2-acetyl-sn-glycerol 135 
cholinephosphotransferase (PAF-CPT, EC 2.7.8.2), which incorporates CDP-choline into 1-O-136 
alkyl-2-acetyl-glycerol to form PAF (44). PAF-CPT and lyso-PAF-AT both catalyze the final 137 
steps in each biosynthetic pathway and exhibit a basic regulatory role in PAF production. It is 138 
hypothesized that the de novo pathway is responsible for endogenous PAF production to 139 
maintain physiological levels, whereas the remodeling route leads to the production of PAF in 140 
response to inflammatory stimuli and is the main pathway involved in inflammatory cascades 141 
(23, 48). A simplified schematic of the remodeling pathway is presented in Figure 2. Long-142 
term induction of PAF-CPT gradually increases systemic PAF levels with related 143 
consequences. Furthermore, PAF-CPT activity contributes to systemic inflammation and age-144 
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related malfunctions of the central nervous system and cancer (23, 49), while its inhibition has 145 
demonstrated beneficial outcomes in several chronic disorders (22, 50-52). 146 
 147 
PAF and cancer 148 
- Angiogenesis and PAF 149 
 The mechanism of angiogenesis, neoangiogenesis, and carcinogenesis is complex and 150 
not completely understood, in which PAF plays a significant role (34). Established tumors can 151 
increase in diameter by 1-2 mm, before their growth is inhibited by an insufficient nutrient and 152 
oxygen supply, therefore the tumor can remain dormant for several years due to the balance 153 
between proliferation and apoptosis. In this state, tumors are capable of further intrusion into 154 
proximal tissues where they can form neoplastic blood vessels driven by the hypoxic 155 
microenvironment. This process precedes metastasis and is known as neoangiogenesis, which 156 
is a promising target for cancer treatment (19-21, 53).  157 
Angiogenesis initiates through the activation of endothelial cells on pre-existing blood 158 
vessels by cancer cells. Chronic inflammatory manifestations facilitate endothelial activation 159 
and may induce cancer cells to secrete angiogenic factors such as PAF (23). These cancer cells 160 
produce growth factors and cytokines that link to their reciprocal receptors in the endothelium, 161 
which trigger membrane signaling pathways that stimulate the vessel. These cytokines can 162 
induce further production of PAF and expression of the PAF-R, which induces the production 163 
of more cytokines in a cyclic manner (23, 34). The activated endothelial cells also degrade the 164 
extracellular matrix (ECM) through the production of metalloproteases and serine proteases. 165 
The endothelial cells express adhesion molecules that create a microenvironment that enhances 166 
the migration and proliferation of endothelial cells from pre-existing vessels through 167 
microtubules that join the circulatory system. These newly established microtubules create a 168 
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functional tumor microenvironment that can continue to proliferate (53, 54). Adhesion 169 
molecules also cause cancer cells to attach to platelets and endothelial cells in newly 170 
synthesized blood vessels, which enables metastasis and subsequent colonization of other 171 
tissues (23, 54).  172 
 Angiogenic factors including cytokines, growth factors, and their specific receptors are 173 
implicated in the induction of tumor neoangiogenesis (55-57). However, targeting of single 174 
growth factors or their corresponding receptors has not been successful due to the ability of 175 
cancer cells to reprogram and produce other growth factors. For example, when targeting 176 
vascular endothelial growth factor (VEGF), tumors adapt by producing basic fibroblast growth 177 
factor (bFGF) instead of VEGF, which induces the proliferation and migration of endothelial 178 
cells (58). Therefore, bi-specific anti-angiogenic inhibitors have been developed that have the 179 
ability to inhibit more than one receptor, such as SU-6668 (58) or Sunitinib (59).  180 
However, endothelium activation and the cascades induced by growth factors share 181 
common pathways, which are related to the production and release of lipid mediators like PAF 182 
and arachidonate (58). When PAF is released in the tumor microenvironment it can affect the 183 
endothelial cells in an autocrine or paracrine mode, which can also affect platelets and cancer 184 
cells (23). Increased levels of circulating PAF initiates a rapid inflammatory response that 185 
results in an increased permeability of the endothelium and other significant biological 186 
responses (23), such as: 1) the increased expression of PAF-R and production of PAF by 187 
endothelial cells, platelets, and cancer cells; 2) the induction of cellular proliferation; 3) 188 
prostaglandin production via COX-2 activation; 4) expression of metalloproteases and serine 189 
proteases through the activation of the Janus tyrosine kinases (JAKs) signaling cascades and 190 
signal transducers and activators of transcription (STATs), leading to ECM degradation. These 191 
effects are crucial to the process of angiogenesis and metastasis, which are further discussed in 192 
the next section. 193 
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 194 
- PAF, Metastasis, and Cancer 195 
Several studies have indicated that PAF may be produced and PAF-R may be expressed on 196 
cell membranes of activated endothelium and/or cancer cells in the tumor microenvironment 197 
(22, 34, 49, 60-62). Cytokines and growth factors such as VEGF, FGF, and TNF-α induce PAF 198 
production (54, 63). PAF produced by these cytokines further stimulates the production of 199 
inflammatory cytokines, which promotes metastasis through activation of the NF-κB pathway 200 
via toll-like receptors (64-66). The NF-κB pathway controls the expression of pro-201 
inflammatory cytokines (TNF-α, FGF, IL-1, IL-2, and IL-6), chemokines (IL-8, MIP-1α, and 202 
MCP-1), adhesion molecules (ICAM, VCAM, and E-selectin), acute-phase proteins, immune 203 
receptors, growth factors, and inducible enzymes (VEGF, COX-2, MMPs, iNOS), which are 204 
all implicated in inflammation, angiogenesis, or in tumor cell or endothelial cell proliferation, 205 
adhesion, migration, and invasion (67). It has been reported that PAF induces NF-κB activation 206 
in intestinal epithelial cells by enhancing IκBα phosphorylation (68). Furthermore, reactive 207 
oxygen species (ROS) activate CK2 via p38, which in turn induces NF-κB activation. 208 
Subsequently, PAF, LPS, and TNF-α increase pulmonary tumor metastasis through the 209 
induction of ROS/p38/CK2/NF-κB pathway (66). The interactions and relationships between 210 
many of these inflammatory molecules and their effects in relation to PAF and cancer are 211 
presented in Figure 3.   212 
PAF overexpression correlates with malignancy of various tumors (34, 54). Elevated 213 
levels of PAF and PAF-R transcripts 1 and 2 are evident in hepatocellular carcinoma specimens 214 
in comparison to non-carcinoma specimens (69). In breast cancer, cells that express higher 215 
ability to synthesize and release PAF are more malignant with a higher capability to 216 
metastasize, which also express more PAF-R on their membranes (54). PAF may be involved 217 
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in breast cancer initiation as well as promotion by enhancing the migratory ability of cancer 218 
cells mediated via PI3-kinase and/or the Jun N-terminal kinase (JNK) pathway and is 219 
independent of the MAPK pathway (26). PAF also induces the transformation of non-220 
tumorigenic cells (26). PAF overexpression in pancreatic cancer leads to cell proliferation and 221 
tumorigenesis. It has also been shown that PAF ectopic activation of the phospholipid-222 
regulating MAPK signaling pathway via the activation of LAM TOR3 pathway, caused 223 
neoplasia in pancreatic cancer. Thus, PAF may be a biomarker for targeted therapy in 224 
pancreatic cancer (70).  225 
PAF seems to be heavily implicated in digestive cancers. Levels of PAF-AH and PLA2 226 
are elevated in patients with colon cancer (71) and elevated PAF levels have been observed in 227 
metastatic colon cancer (72, 73). Likewise, PAF-R is strongly expressed in esophageal 228 
squamous cell carcinoma, PAF-R levels are positively correlated with malignancy in 229 
esophageal squamous cell carcinoma (74), and lysophosphatidylcholine acyltransferase 1 230 
overexpression promotes oral squamous cell carcinoma progression via enhanced biosynthesis 231 
of PAF (75). Interestingly, PAF-R expression is also increased in patients with gastric 232 
adenocarcinoma, which is associated with organ metastasis. However, increased PAF-R 233 
expression was also significantly associated with higher tumor differentiation, smaller tumor 234 
size, absence of lymph nodes, and low tumor histopathological stage in adenocarcinoma 235 
patients who had significantly longer survival times compared to those with low PAF-R 236 
expression (76). These occurrences seem contradictory considering that increased PAF-R 237 
expression is correlated with malignancy in esophageal squamous cell carcinoma but smaller 238 
tumor size in gastric adenocarcinoma. However, the morphological features such as smaller 239 
tumor size etc. that correlate with high PAF-R expression are characteristic features of gastric 240 
cancer. These features are the reason that gastric cancer is considered slow and progressive 241 
(77), thus leading to longer patient survival (78); however, it is important to note that gastric 242 
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cancer is still malignant and the third leading cause of cancer-related death worldwide (77). It 243 
may also be the case that the high expression of PAF-R is also a characteristic of gastric cancer, 244 
since high expression of the PAF-R may induce apoptosis (79), thus explaining why gastric 245 
cancers are slow to develop and grow, but are still lethal as they can metastasize to other organs 246 
(77). Therefore, the expression of the PAF-R in gastric cancer may have some prognostic value, 247 
but the role of PAF and the PAF-R in digestive cancers is complex and further extensive 248 
research is necessary.  249 
PAF is present in human meningiomas where it is believed to act on tumor growth by 250 
altering the local angiogenic and/or cytokine networks as previously seen in human breast 251 
cancer and colorectal cancer (80). A recent study has indicated that PAF can alter the 252 
permeability of the blood-brain barrier (81), this may prove important for central nervous 253 
system inflammatory disorders, including cancer. PAF and PAF-R may also play a major role 254 
in prostate cancer (82).  255 
Ultraviolet (UV) radiation is the primary cause of non-melanoma skin cancer and UV 256 
exposure is implicated in the induction of melanoma, the most severe form of skin cancer. As 257 
well as being carcinogenic, UV light is immunosuppressive (83). PAF and PAF-like lipids are 258 
produced by epidermal keratinocytes in response to UVB radiation (84, 85) and are linked to 259 
systemic immune suppression (35, 86), which is a major risk factor for skin cancer 260 
development (87). Although PAF-like lipids are produced and involved in the inflammatory 261 
milieu, they possess only 10% the potency of native PAF (36). Dermal mast cell migration 262 
from the skin to the draining lymph nodes plays a crucial role in activating immune 263 
suppression. PAF produced by UV-induced keratinocytes upregulates the expression of 264 
CXCR4 on the surface of mast cells (88). In addition, PAF upregulates CXCR4 ligand 265 
expression on lymph node cells, therefore directing the mast cell migration from the skin to the 266 
draining lymph node, where mast cells secrete IL-10 and suppress the immune response (89). 267 
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PAF synthesis by keratinocytes in response to UVB radiation is enhanced by the 268 
overexpression of the PAF-R and is inhibited by PAF-R antagonists such as WEB 2086 (90). 269 
Additionally, in B16F10 murine melanoma PAF-R antagonists decreased lung metastasis (91). 270 
Therefore, inhibition of the actions of PAF by the action of PAR-R antagonists may be a 271 
therapeutic target for the prevention of some cancers.  272 
It was previously reported that PAF may not play a role in some human lung cancers 273 
(92). However, murine models have revealed that PAF-R antagonists can augment tumor 274 
growth and lung cancer metastasis in a PAF-R-dependent manner (93). Although PAF is 275 
critical in some cancers, it seems there is not conclusive evidence to suggest that PAF is 276 
implicated in all cancers, such as thyroid cancer (94). However, there is limited research 277 
regarding the role of PAF in various other cancers. Evidence for the role of PAF in various 278 
cancers is presented in Table 1.  279 
 Notably, PAF may exhibit beneficial effects on some cancer cells. For example, it was 280 
shown that the loss of the PAF-R in mice augmented PMA-induced inflammation and chemical 281 
induced carcinogenesis, indicating that the PAF-R may suppress PMA-induced inflammation 282 
and neoplastic development in response to chemically-induced carcinogenesis (95). 283 
Furthermore, elevated expression of the PAF-R can enhance cell apoptosis through the 284 
activation of NF-κB (79, 96), which is due to the dual action of the NF-κB pathway in 285 
malignancy and apoptosis through the immune response (97), which has been extensively 286 
reviewed by Tsoupras et al (23).  287 
Several conclusions can be drawn from the relationship between PAF, PAF-R, and cancer. 288 
It is unknown how PAF becomes present in the tumor environment initially. It is proposed that 289 
activated endothelial cells, leukocytes, and/or platelets may synthesize PAF, which can activate 290 
other cells to produce more PAF in a autocrine, paracrine or juxtacrine way (23). Cancer cells 291 
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themselves synthesize PAF, which may induce neighboring cells to synthesize PAF in a similar 292 
fashion (23). Therefore, as cancer cells have the autonomy to produce PAF and express PAF-293 
R on their membrane, PAF plays an integral role in cancer malignancy (34). While PAF is not 294 
the only mediator of inflammation involved in the complex inflammatory mechanisms of 295 
cancer, it is one yet to be fully explored or elucidated and deserves further attention for the 296 
development of therapeutic measures.  297 
 298 
- Types of PAF Inhibitors and Cancer 299 
Several molecules, both of synthetic (98) and natural (10) origins, have been described that 300 
demonstrate inhibitory effects against PAF-induced biological activities. These molecules act 301 
directly through antagonistic/competitive displacement of PAF in the PAF-R or through other 302 
indirect mechanisms. These indirect mechanisms have not yet been fully elucidated, however 303 
it is proposed that changes in the lipid rafts and membrane microenvironment of the PAF-R 304 
and/or the antioxidant capacity of these molecules may be responsible (10, 23). In addition, 305 
some PAF inhibitors such as dietary polar lipids demonstrate beneficial effects against PAF 306 
metabolism by downregulating PAF synthesis and upregulating PAF catabolism (22, 99, 100).  307 
Many studies have focused on synthetic PAF inhibitors that modulate PAF metabolism (52) 308 
such as Rupatadine, which is used in the treatment inflammatory conditions like allergies (101-309 
103) or cisplatin for cancer treatment (104). In addition, natural PAF-R antagonists have been 310 
described; the most well-known being ginkgolides A and B (105). Ginkgolides are a family of 311 
molecules derived from Ginkgo biloba  tree (105), which can also modulate PAF metabolism 312 
in chronic diseases (50). In cancer, ginkgolide B has exhibited beneficial effects through 313 
inhibiting tumorigenesis and angiogenesis in azoxymethane/dextran sulfate sodium induced 314 
colitis-associated cancer in mice (106), in which tumor number and load was reduced, while 315 
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serum PAF-AH activity and thus PAF catabolism was increased and VEGF expression and 316 
microvessel density decreased following treatment with Ginkgolide B. The effects of various 317 
PAF-R antagonists including BN-50730 and WEB-2170, which exhibit anti-cancer effects 318 
through their anti-PAF activities (23, 52, 107, 108) as reviewed by Tsoupras et al. (23).  319 
 320 
- Conventional Cancer Treatment and PAF-Receptor Antagonists 321 
Traditional cancer treatment involves chemotherapy and radiation treatments. To date there 322 
are no PAF or PAF-R related cancer treatments available. Many in vitro and in vivo studies 323 
indicate that the co-treatment with PAF-R antagonists and chemotherapeutic drugs may have 324 
better antineoplastic effects. It has been shown that PAF-R-dependent pathways are activated 325 
during experimental tumor growth, altering the tumor microenvironment and cause the 326 
polarization of macrophages, which favors tumor growth; combination therapy of a PAF-R 327 
antagonist (WEB2170) and a chemotherapeutic drug (dacarbazine, DTIC) reduced tumor 328 
volume in mice, and the survival of tumor-bearing animals improved when both treatments 329 
were used in combination in a murine model of melanoma (109). Another study treated a 330 
SKmel37 human melanoma cell line with cisplatin, which led to increased expression of PAF-331 
R and its accumulation. In the presence of exogenous PAF, melanoma cells were significantly 332 
more resistant to cisplatin-induced cell death. However, the use of a PAF-R antagonist 333 
WEB2086 demonstrated inhibition of PAF-R-dependent signaling pathways and exhibited 334 
chemosensitization of melanoma cells in vitro. In the same study, nude mice, that were 335 
inoculated with SKmel37 cells and treated with cisplatin and WEB2086 showed significant 336 
decreases in tumor growth compared to mice with only one treatment agent and controls. These 337 
results suggest that activation of the PAF-R pathways may support tumor survival and tumor 338 
repopulation in melanomas (110). Similarly, an in vivo study demonstrated that cisplatin 339 
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induced an increase of PAF-R expression in SKOV-3 and CAOV-3 human ovarian cancer cell 340 
lines. The upregulation of PAF-R by cisplatin correlated with a time-dependent accumulation 341 
of HIF-1α and NF-κB in the nucleus. The inhibition of PAF-R by Ginkgolide B sensitized the 342 
ovarian cells to cisplatin treatment due to the blockade of the ERK and PI3K pathways 343 
downstream of activated PAF-R. Furthermore combined treatment of ovarian cancer cells of 344 
Ginkgolide B and cisplatin reduced tumor growth (111). PAF-R antagonists may also treat 345 
intestinal mucositis as demonstrated in murine models, which is a common side effect of cancer 346 
chemotherapy (112).  347 
Radiotherapy is important for the treatment of many cancers. Ionizing radiation is used to 348 
selectively kill tumor cells and spare normal tissue. Ionizing radiation causes significant 349 
damage to a wide variety of targets in tumor cells but it mainly causes disruption to DNA and/or 350 
DNA replication or repair mechanisms, which play a major role in radiation-induced cell death 351 
(113). However, ionizing radiation can also cause the generation of ROS (114). Pro-oxidative 352 
stressors can suppress host immunity due to their ability to generate oxidized lipids and PAF-353 
R agonists. Sahu et al. have shown that radiation exposure of multiple tumor cell lines in vitro 354 
and in vivo, along with human subjects undergoing radiation therapy for skin tumors, all 355 
generate PAF-R agonists, which can induce several pro-inflammatory signaling pathways. 356 
Their structural analysis has revealed that radiation therapy leads to the non-enzymatic 357 
production of multiple oxidized glycerophosphocholines that are PAF-R agonists and PAF 358 
itself (115). In a murine melanoma tumor model, irradiation of one tumor led to alterations in 359 
non-treated tumors in a PAF-R-dependent process that could be blocked by cyclooxygenase-2 360 
inhibitor. Therefore, the occurrence of PAF-R agonists as a by-product of radiation therapy 361 
could result in treatment failure. Similar results were observed in a recent study that 362 
demonstrated that PAF-like molecules with agonistic properties are generated by radiotherapy 363 
and through their action on tumor cells protects them from radiation-induced cell death by 364 
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acting on macrophages. Such PAF-like molecules stimulate tumor growth through 365 
immunosuppression. Therefore, the association of radiotherapy with the PAF-R antagonists 366 
represents a promising strategy for improving the efficacy of radiotherapy (116). 367 
In a series of experiments by da Silva-Junior et al. (117), cervical cancer patients who 368 
underwent radiotherapy had a significantly higher expression of PAF-R. In addition, cervical 369 
cancer-derived cell lines (C33, SiHa, and HeLa) and squamous carcinoma cell lines (SCC90 370 
and SCC78) express higher levels of PAF-R mRNA and protein than immortalized 371 
keratinocytes. Gamma radiation also increased PAF-R expression and induced PAF-R ligands 372 
and prostaglandin E2 in these tumor cells. The inhibition of PAF-R activities with the 373 
antagonist CV3938 before irradiation inhibited prostaglandin E2 and increased tumor cell 374 
death. Similarly, human carcinoma cells transfected with PAF-R were more resistant to 375 
radiation compared to those lacking the receptor. prostaglandin E2 production by irradiated 376 
cells transfected with PAF-R were also inhibited by CV3988. These results show that 377 
irradiation of carcinoma cells generates PAF-R ligands and higher PAF-R expression that 378 
protects tumor cells from death and suggests that the combination of radiotherapy with PAF-R 379 
antagonists could be a promising strategy for cancer treatment.  380 
 381 
Nutrition and Cancer 382 
The links between diet and cancer have been substantiated in several epidemiological 383 
studies (118). The World Cancer Research Fund International (WCRF)/American Institute for 384 
Cancer Research (AICR) has collated and summarized published research on the relationships 385 
among cancer prevention and survivorship and diet, nutrition, and physical activity. Its Second 386 
Expert Report was published in 2007 (119) and the  WCRF/AICR have since been publishing 387 
cancer prevention research from around the world. It is clear from these reports that a healthy 388 
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diet can play a key role in the prevention of cancer. In fact, they have estimated that for the 13 389 
most common cancers, at least 29% of cases in the United States and the United Kingdom 390 
could be prevented by adhering to a healthy diet and lifestyle (120), if the research can be 391 
translated to preventive interventions, and the literature cited is valid (121).  392 
 393 
- Nutrition and Cancer Prevention – Inhibiting Inflammation  394 
Carcinogenesis is a multi-mechanism process consisting of initiation, promotion, and 395 
progression phases. Diet can affect any of these phases, but an efficacious strategy for dietary 396 
chemoprevention would be intervention during the promotion phase due to its associations with 397 
inflammation. The tumor-promotion process requires sustained exposure to agents that 398 
stimulate the growth and inhibition of apoptosis of initiated cells in the absence of anti-399 
promoters (122).  400 
A maladaptive diet and lifestyle are key modifiable risk factors for the prevention of 401 
systemic inflammation (123). The majority of tumor promoting conditions and agents, 402 
reversibly, inhibit cell-cell communication. However, antioxidants and anti-inflammatory 403 
agents are capable of ameliorating the effects of tumor promotors on cell–cell communication 404 
(122). Inflammatory mediators such as PAF are key molecules in cell-cell communication (10). 405 
Research demonstrates that many nutrients can modulate the immune response to act against 406 
cancerous cells, but not against adjacent cells (122, 124, 125). Certain dietary components have 407 
been proposed as possible PAF-R antagonists that may ameliorate PAF related neoplastic 408 
mechanisms (23). However, lifestyle factors are also important. For example, smoking directly 409 
affects metastatic disease via inhibition PAF-AH, resulting in the accumulation of PAF-like 410 
agonists and an increase in cell motility in breast cancer cells (126)  411 
 412 
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- PUFA and Polar Lipids in PAF related Cancer Prevention 413 
Many nutrients seem to possess antioxidant, anti-proliferative, and antiangiogenic 414 
properties that prevent the spread of cancer (23, 127). Several foods and supplements contain 415 
antioxidants that exhibit antineoplastic activities that function far beyond antioxidant activity 416 
alone, but also operate through direct inhibition of PAF activity and down regulation of PAF 417 
levels (23). Long chain ω3 PUFA possess multiple anti-inflammatory properties including the 418 
reduction in the synthesis of proinflammatory eicosanoids, reduction of leukocyte and platelet-419 
adhesive endothelial interactions, inhibition of inflammatory gene expression, and stimulation 420 
of glutathione production, which can decrease oxidative injury (128, 129). Immunonutritional 421 
support in cancer treatment may modulate the immune response and improve cancer patient 422 
outcomes (129); in a double-blind study, nutritional status and inflammatory markers were 423 
improved in 40 patients with stage III non-small cell lung cancer during multimodality 424 
treatment who had taken ω3 PUFA supplements (130). Evidence suggests that ω3 PUFA 425 
supplementation may be useful  in anti-cachectic therapy, and may reduce the levels of CRP 426 
and IL-6 during chemotherapy treatment of lung cancer (131). In a similar study, pancreatic 427 
cancer patients were supplemented with low doses of ω3 PUFA fish oil or marine 428 
phospholipids for six weeks. Both supplements resulted in significant weight stabilization at 429 
very low doses (300mg per day), an improved appetite, and quality of life. The phospholipid-430 
based supplement was better tolerated than the fish oil supplement. Furthermore, both 431 
supplements increased the patient’s ω3 concentration of plasma triglycerides and 432 
phospholipids (132).  433 
Similar outcomes were observed in patients with various tumors, who suffered tumor-434 
associated weight loss (133). It has been concluded that ω3 PUFA supplementation during 435 
chemotherapy improves patient outcomes related to tolerability, regardless of the 436 
chemotherapy used (134). The mechanisms by which ω3 PUFA improves patient 437 
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chemotherapy tolerability are unclear (134). Positive outcomes in patients’ health may be due 438 
to the anti-inflammatory properties of the marine phospholipids and ω3 PUFA, which have 439 
both demonstrated anti-PAF activities and whose effects have recently been reviewed (10). The 440 
benefits of marine PUFA supplements as an adjuvant to chemotherapy have been 441 
comprehensively reviewed (134, 135).  442 
Systemic inflammation is implicated in atherosclerosis (22, 123) and glomerulosclerosis 443 
(136). Since atherosclerosis and glomerulosclerosis share common features with those of 444 
cancer angiogenesis and metastasis, several molecules with pleiotropic activities such as anti-445 
atherogenic and antithrombotic molecules including warfarin, statins, vitamin D analogues, 446 
and non-steroidal anti-inflammatory molecules such as COX-2 inhibitors have demonstrated 447 
beneficial effects against cancer (137, 138). Several of these treatments exhibit inhibitory 448 
effects against the bioactivities of PAF and its biosynthetic enzymes (52). Polar lipids 449 
(phospholipids, sphingolipids, glycolipids, and phenolic lipids) that are widely distributed in 450 
foods have the capacity to inhibit the biological actions of PAF (10). These lipids are 451 
structurally specific and bind to the PAF-R directly or indirectly (10). Polar lipids extracts from 452 
marine and dairy sources (10, 99, 123, 139) have demonstrated the ability to inhibit PAF-453 
induced platelet aggregation in animal and human platelets in cardiovascular related studies. 454 
These studies investigate the potential of various food lipids to inhibit the binding of PAF to 455 
the PAF-R through direct antagonistic or competitive binding. Observing the inhibition of 456 
PAF-induced platelet aggregation by dietary polar lipids allows for the identification of PAF-457 
R antagonists. These studies identified phosphatidylcholine and phosphatidylethanolamine 458 
derivatives as the biologically active polar lipids against the actions of PAF (10, 140), which 459 
also had the ability to modulate PAF metabolism, with beneficial outcomes against 460 
atherosclerosis (10, 51, 100, 141).  461 
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Therefore, it is logical to propose that molecules that can inhibit the binding of PAF to 462 
PAF-R and its subsequent signaling pathways, may possess the same beneficial biological 463 
activities in cancer. Certainly in vitro  and in vivo studies indicate that polar lipid compounds 464 
can affect PAF metabolism (100) and have anti-proliferative effects against human ovary and 465 
colon cancer cells (142), although not all of the mechanisms are fully elucidated. In particular, 466 
phosphatidylcholine may induce apoptosis (143) and inhibit DNA synthesis in colon cancer 467 
(144).  Furthermore, polar lipids and phenolic compounds in red and white wine have also 468 
demonstrated antiproliferative effects in prostate cancer cells (PC-3) (145). These effects were 469 
attributed to their antioxidant effects, as the PAF pathway was not assessed. 470 
Dairy products are consumed in moderation in most dietary patterns. Polar lipids isolated 471 
from bovine, ovine, and caprine dairy products have exhibited potent inhibition of PAF-472 
induced platelet aggregation in vitro (146-149). Interestingly, caprine and ovine milk lipids 473 
seem to possess greater anti-PAF activity in contrast to bovine milk lipids and that fermented 474 
products may exhibit greater bioactivity (150). This is attributed to the structural differences 475 
between these polar lipids.  476 
Studies directly investigating dietary polar lipids with anti-cancer activities are limited. 477 
However, a food grade extract rich in polar lipids from the milk fat globule membrane of 478 
buttermilk were strongly antiproliferative against human ovary and colon cancer cells 479 
(OVCAR-3 and HT29) (142). Similarly, buttermilk polar lipids inhibited the growth of SW480 480 
colon cancer cells in a dose dependent-manner. This study determined that a sphingolipid 481 
fraction mainly composed of lactosylceramide downregulated growth-signaling pathways 482 
mediated by β-catenin, ERK1/2 (extracellular signal-regulated kinase), phosphorylated Akt 483 
(serine/threonine-specific protein kinase), and c-myc (151). Extensive study of sphingomyelin 484 
and related compounds confirms that they play a central role in the control of cell growth, 485 
differentiation, migration, and apoptosis and may have therapeutic value (152, 153). 486 
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Specifically, dairy derived-sphingomyelin is reported to decrease the number of aberrant foci 487 
crypts and protect against colon cancer by inhibiting tumorigenesis and increasing alk-488 
sphingomyelinase in mice fed a concentration of 0.5 g/kg over 22 weeks ad libitum (154) and 489 
the supplementation of 0.005 g/100 g sphingomyelin in the diet of CF1 mice transformed 490 
malignant adenocarcinomas to benign adenomas (155). 491 
Other murine models have shown that dietary supplementation of dairy-derived 492 
sphingomyelin may also be chemopreventative when administered before tumor induction 493 
(154, 156-159). These effects are attributed to ceramide and sphingosine phosphate, which 494 
induce apoptosis by modification of the expression of regulator genes in cancer (160, 161). The 495 
literature suggests that that sphingomyelin may be the most active polar lipid against cancer 496 
(156). Furthermore, these anti-cancer phospholipids seem to share similar compositions to 497 
those that demonstrated inhibition of PAF-induced platelet aggregation and thus the PAF 498 
inflammatory pathway (148). In particular, it has been confirmed that dairy-derived 499 
sphingolipids inhibit the binding of PAF the PAF-R in PAF platelet aggregation studies (146-500 
148). Therefore, it is possible that these molecules may also inhibit PAF-related mechanisms 501 
in cancer, as was been previously postulated (23).  502 
Polar lipids from other sources have exhibited similar effects on various cancer cell lines. 503 
For instance it has been shown that microalgae polar lipids may induce anti-proliferative effects 504 
in MCF-7 breast cancer cells (162), however a similar study of dairy polar lipids did not 505 
observe the same effects (142). This may be due to the differences in the polar lipids 506 
composition or their isolation techniques (156). The same microalgae study also demonstrated 507 
a 50% decrease in growth of hepatic cancer cells (Hep-G2) (162). In a similar in vitro study of 508 
hepatic cell lines (Alexander cell, Hep-3b, Hep-G2, and HuH-7), phosphatidylcholine isolated 509 
from egg yolk inhibited cancer cell growth. A study of the same cells in Sprague-Dawley rats 510 
administered the same polar lipid concentrates (0.05 g/100 g of diet) in an intragastric manner 511 
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over 14 weeks exhibited similar inhibition of growth (163, 164). Similarly, polar lipids may be 512 
beneficial in the treatment and prevention of pancreatic cancer (165). 513 
 Phosphatidylcholine, phosphatidylethanolamine, and sphingomyelin have displayed 514 
positive effects against metastasis in gastric cancer cells (NUGC) by decreasing migration and 515 
adhesion (166). Although not dietary, synthetic phosphatidylethanolamine has demonstrated 516 
various antiproliferative, anti-angiogenic, and anti-metastatic effects in murine renal cell 517 
carcinoma and HUVEC cells. Furthermore, in vivo results show that phosphatidylethanolamine 518 
potentially inhibits lung metastasis in nude mice, with a superior efficacy when compared to 519 
Sunitinib (167). Although not specified in these studies, it is likely that inhibition of the PAF 520 
pathway could play a role. Considering these findings, further research should address the 521 
possible role of dietary phospholipids for the prevention of neoangiogenesis, cell proliferation, 522 
and metastasis through the PAF pathways. 523 
 Other nutrients including phenolic-lipids like resveratrol, yuccaols, and 524 
epigallocatechin-3-gallate found in various foods also exhibit beneficial effects against the PAF 525 
inflammatory pathways (52, 108, 168). However, there is a lack of substantial mechanistic 526 
evidence to explain their observed effects.  527 
 The Mediterranean diet and cancer 528 
- The traditional Mediterranean diet and cancer prevention 529 
Several studies have linked the Mediterranean diet to lower risk of cardiovascular disease 530 
(169). Evidence suggests that this may extend to lower incidences of other chronic diseases 531 
mediated by inflammation including diabetes (170), cerebrovascular disease (171) cancers of 532 
the digestive system (172-175), breast cancer (176), overall types of cancer (177, 178), and 533 
premature mortality in general (179). The traditional Mediterranean diet is broadly 534 
characterized by high fruit, vegetable, legume, bread, cereal foods composed of wheat, tree 535 
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nuts, and olive oil consumption, including moderate helpings of milk and dairy products, and 536 
low intake of red meat (24). Wine is also consumed within moderation in non-Islamic regions. 537 
Coffee is considered the hot beverage of choice and is generally consumed with sugar (119). 538 
The compounds and nutrients found in the Mediterranean diet seem to exhibit bioactivities 539 
against PAF-related inflammation, cancer development, and metastasis. Detopoulou et al. 540 
(180) examined the effects of nutrition, lifestyle, and biochemical variables of 106 subjects. 541 
Dietary patterns and food constituents containing bioactive molecules were inversely related 542 
to PAF levels or its biosynthetic enzymes. It is uncertain whether this association is facilitated 543 
by the attenuation of subclinical inflammation induced by an antioxidant-rich diet or is it a 544 
direct action of antioxidants on PAF metabolism. Nevertheless, this association illustrates a 545 
potential mechanism of the diet–disease hypothesis.  546 
 It has been proposed that the Mediterranean diet may in part exert some of the observed 547 
beneficial effects through dietary PAF antagonists such as polar lipids, which reduce PAF-548 
related cascades implicated in platelet activation, aggregation, and inflammation (10, 24, 148, 549 
181, 182) as many foods of the Mediterranean diet are rich in compounds with anti-PAF 550 
biological activities (Table 2). A clinical study has demonstrated that meals high in PAF 551 
antagonists improved the platelet response of type II diabetics and healthy humans against 552 
inflammatory and prothrombotic factors (183). A similar study demonstrated that the 553 
traditional Greek Mediterranean diet can reduce platelet activity in type II diabetics and healthy 554 
volunteers due to the effects of PAF antagonists on PAF- and ADP- induced platelet 555 
aggregation (181). Although the molecular mechanisms have not been fully elucidated yet, 556 
diets that contain high levels of PAF antagonists may play a role in inhibiting the biological 557 
actions mediated by PAF, thus potentially lowering the risk of cancer. Indeed, other similar 558 
healthy dietary patterns such as the Nordic diet may also exert its beneficial effects against 559 
cancer in part via dietary PAF inhibitors and related anti-inflammatory mechanisms (184). 560 
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Furthermore, it is not clear whether the presence of other health conditions (e.g. cardiovascular 561 
diseases, obesity, etc.) in patients with cancer may compromise or improve the efficacy of 562 
dietary PAF inhibitors against PAF, and subsequently cancer; thus, further research is 563 
warranted. Some of the foods and compounds of the Mediterranean diet that exhibit these 564 
effects are summarized in Table 2.    565 
 566 
- Cancer incidence and the Mediterranean diet 567 
 A recent meta-analysis that included 83 studies assessed the adherence to the 568 
Mediterranean diet on the risk of overall cancer mortality and the risk of various cancers in a 569 
total of 2,130,753 subjects. It was found that the highest adherence score to a Mediterranean 570 
diet was inversely associated with a lower risk of cancer mortality, head and neck cancer, breast 571 
cancer, gastric cancer, liver cancer, colorectal cancer, and prostate cancer. However, the 572 
association between the adherence to the highest Mediterranean diet category and the risk of 573 
cancer mortality and cancer recurrence in survivors was not statistically significant. 574 
Furthermore, it was demonstrated that these protective effects were associated with high fruit, 575 
vegetable, and whole grain intake (185). Other studies have demonstrated similar results with 576 
varying levels of statistical strength for overall cancer and specific cancers (172, 175, 186-577 
188), in particular in southern Europe, adherence to the Mediterranean diet was associated with 578 
a 6% reduction in cancer mortality (177). It is clear that adherence to the Mediterranean diet is 579 
associated with a reduction in mortality and morbidity, which is due to the types of foods 580 
consumed and the nutrients that the diet provides and they possess anti-inflammatory 581 
bioactivities (189). Hence, the presence of nutrients that have the capacity to inhibit PAF and 582 
related inflammatory pathways may in part play a significant role in inflammation and cancer. 583 
While PAF plays a central role in several key mechanisms of cancer development and 584 
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progression, and there is a plethora of inflammatory pathways interlinked in an exceedingly 585 
complex process, it is important to note that blocking one inflammatory mediator is not a 586 
panacea.  Dietary PAF inhibitors may have the potential to prevent the physiological actions 587 
of PAF in cancer, but it must be acknowledged that this is only one of many mechanisms. The 588 
adherence to healthy dietary patterns rich in microconstituents with anti-inflammatory 589 
bioactivities such as those of the Mediterranean diet, may in part aid in impeding multiple pro-590 
inflammatory mechanisms.  591 
However, concern has been raised that the traditional Mediterranean dietary patterns 592 
are gradually becoming less common as the food supplies of the countries of the Mediterranean 593 
littoral become increasingly ‘Western’ (119). The Western diet is associated with high intake 594 
of processed food, which may lead to anywhere between 25% - 50% of total daily energy 595 
intake, which is synonymous with the U.S. (190). A recent perspective cohort study found that 596 
a 10% increase in the proportion of ultra-processed foods in the diet was associated with a 597 
significant increase greater than 10% in risks of overall cancer and breast cancer (191). 598 
Furthermore, there is evidence of a higher risk for colorectal cancer in Western societies where 599 
there is higher consumption of processed meat and red meat, although there are concerns that 600 
red meat itself unprocessed may not be negatively associated with colorectal cancer risk (192). 601 
This is in contrast to those who adhere to the Mediterranean diet that benefit with lower overall 602 
cancer mortality (193). A recent study has demonstrated that adherence to a Western style diet 603 
was related to an increased risk of breast cancer, especially in premenopausal women. Whereas, 604 
the Mediterranean diet was related to a lower risk. These observations were again attributed to 605 
a diet high in fruits, vegetables, and oily fish (175). Therefore, it is clear that the modern 606 
Mediterranean regions should adhere to their traditional dietary patterns, as Westernization 607 
may lead to an increase of chronic diseases including cancers.  608 
 609 
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Future Research Perspectives 610 
 PAF plays a central role in digestive, skin, breast, and reproductive cancers, but may 611 
not be involved in other cancers and has demonstrated attenuating effects in some cancers. 612 
Many studies have demonstrated that PAF-R antagonists may inhibit cancer growth and affect 613 
PAF metabolism in several cancers. Additionally, PAF antagonists may be useful as an 614 
adjuvant therapy for current chemotherapy and radiation treatments. Certainly, the PAF 615 
pathway is a novel target for developing cancer treatments and recently PAF was proposed as 616 
a biomarker of cancer. In light of these findings, several dietary PAF inhibitors such as polar 617 
lipids present in various components of the Mediterranean diet may affect cancer occurrence 618 
and development. Furthermore, the Mediterranean diet is associated with a lower incidence of 619 
various cancers. Many compounds of the Mediterranean diet exhibit anti-PAF activities, which 620 
may be partly responsible for some of these beneficial observations. However, these anti-621 
inflammatory mechanisms have yet to be fully elucidated and further molecular studies are 622 
required to decipher the precise mechanisms that govern PAF-induced inflammation, 623 
angiogenesis, and metastasis. Although the PAF pathway may be an attractive therapeutic 624 
target for various inflammatory diseases, it is not yet certain whether this would be 625 
advantageous to inhibit PAF in human cancer. Therefore, randomized controlled trials are 626 
required to assess the use of PAF-R antagonists as an adjuvant mode of treatment in cancer.  627 
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Table 1: The role of PAF in various cancers. 1305 
Cancer Type Role of PAF and PAF-R 
 
Reference 
Breast cancer cells Increased PAF production and PAF-R expression promotes migration, 
proliferation of tumor cells, and neoangiogenesis 
 
(26, 54) 
Colon cancer PAF-AH and PLA2 are elevated in patients. Metastatic colon cancer 
cells exhibit elevated levels of PAF 
(71-73) 
   
Esophageal squamous cell 
carcinoma (ESCC) 
PAF-R is overexpressed in OSCC and correlated with malignancy. 
Lysophosphatidylcholine acyltransferase 1 overexpression promotes 
OSCC progression via enhanced biosynthesis of PAF 
 
(74, 75) 
Gastric Cancer PAF-R expression is increased in patients with gastric 
adenocarcinoma and is associated with higher tumor differentiation, 
smaller tumor size, absence of lymph node, and organ metastasis, 
and low tumor histopathological stage. Patients with elevated PAF-R 
expression have significantly longer survival times compared to 





Elevated levels of PAF and PAF-R involved in the angiogenic 
response in HCC 
(69) 
   
Lung cancer The role of PAF in lung cancer is not clear; PAF-R antagonists can 
augment tumor growth and lung cancer metastasis in a PAF-R-
dependent manner in murine models. In a double-blind study, 
nutritional status and inflammatory markers were improved in 40 
patients with stage III non-small cell lung cancer during 
multimodality treatment who had taken ω3 PUFA supplements. ω3 
PUFA supplementation may possess anti-cachectic effects and 
reduce inflammatory markers during chemotherapy treatment of 
advanced inoperable non-small-cell lung cancer 
 
(93, 130, 131) 
Pancreatic cancer PAF overexpression in pancreatic cancer leads to cell proliferation 
and tumourigenesis through MAPK signaling 
 
(70) 
Renal cell carcinoma 
(RCC) 
CD154-induced PAF production and PAF-R expression stimulate 
cell proliferation motility, growth, and dissemination of RCC 
 
(194) 
Skin Cancers - melanoma and 
non-melanoma 
PAF and PAF-like lipids are produced by epidermal keratinocytes in 
response to UVB radiation and are linked to UVB-induced systemic 
immune suppression. PAF synthesis is enhanced by the 
overexpression of the PAF-R 
 
(35, 84-86, 90) 
1 
HCC, hepatocellular carcinoma; ESCC, esophageal squamous cell carcinoma; PAF, platelet-activating 1306 
 factor; PAF-AH, platelet-activating factor acetylhydrolase; PAF-R, platelet-activating factor-receptor; 1307 
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Table 2: Studies examining the anti-PAF activities of whole foods and polar lipid extracts in 1314 
the Mediterranean diet. 1315 
Studied Food and Components Study Type Results 
 
PL of fish (Cod, coley, haddock, 
mackerel, salmon, sardines, seabass, and 
seabream) 
 
In vitro studies in WRP, 
hPRP, and HMCs 
Ex vivo studies in hPRP 
In vivo studies in 
hyperlipidemic rabbits 
 
Inhibition of PAF-PA  
Modulation of PAF metabolism towards reduced 
PAF levels and reduction of atherosclerotic lesions in 




PL of olive oil and olive pomace 
 
 
In vitro studies in WRP 
and HMCs  





Inhibition of PAF-PA  
Modulation of PAF metabolism towards reduced 
PAF levels and reduction of atherosclerotic lesions in 
hypercholesterolaemic rabbits and regression of 
existing lesions (201, 202) 
 
PL of dairy products In vitro studies in WRP 
and hPRP 
 
Inhibition of PAF-PA (146-148) 
 
PL of goat and sheep meat Ex vivo studies in hPRP Inhibition of PAF-PA (203) 
PL of seed oils (corn, sesame oil, 
sunflower oil) 
 
In vitro studies in WRP Inhibition of PAF-PA (204) 
 
PL of hen eggs In vitro studies in WRP Inhibition of PAF-PA (205) 
 
PL of red and white wine, musts, grape 
skins, and yeast 
In vitro studies in WRP 
and U937 macrophages 
Postprandial dietary 
intervention studies in 
humans 
Ex vivo studies in hPRP 
 
 
Inhibition of PAF-PA 
Modulation of PAF metabolism towards reduced 
PAF levels (99, 100, 206-209) 
 
PL of honey  In vitro studies in WRP Inhibition of PAF-PA (210) 
 
EOE of garlic & onion  In vitro studies in WRP Inhibition of PAF-PA (211, 212) 
 
Wild plants of the Mediterranean diet 
(Reichardia picroides, Cynara 
cardunculus, Urospermum picroides, and 
Chrysanthemum coronarium)  
 
In vitro studies in WRP 
Postprandial dietary 
intervention studies in 
humans 
Reduced postprandial platelet hyperaggregability of 
metabolic syndrome patients 
Inhibition of PAF-PA ex vivo 
Inhibition of PAF-PA in vitro (213) 
Compounds of the Mediterranean diet 
found in oils, herbs, spices, tea, wine, 
etc. (PL, hesperidin, luteolin, naringin, 
oleic acid, oleuropein, 
proanthocyanidins, quercetin, resveratrol, 
tyrosol) 
In vitro studies in WRP 
and hPRP 
In vitro and in vivo 
studies on various cells 
Ex vivo studies in hPRP 
Postprandial dietary 
intervention studies in 
humans 
 
Inhibition of PAF-PA (214, 215) 
Modulation of PAF metabolism towards reduced 
PAF levels (168, 216, 217) 
1 EOE, essential oil extract; HMCs, human mesangial cells; hPRP, human platelet-rich plasma; PA, platelet 1316 
aggregation; PAF, platelet-activating factor; PL, polar lipids; WRP, washed rabbit platelets 1317 
 1318 
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List of Figure Legends:  1319 
 1320 
Figure 1: The structure of platelet-activating factor.  1321 
 1322 
Figure 2: The remodeling pathway of PAF and lyso-PAF biosynthesis. PAF-AH converts 1323 
active PAF to the inactive lyso-PAF by the loss of an acetate group at the sn-2 position. Lyso-1324 
PAF AT converts lyso-PAF back to the active PAF by the reincorporation of an acetate back 1325 
to the sn-2 position. Acetyl-CoA, acetyl coenzyme A; AT, acetyltransferase; Lyso-PAF, lyso-1326 
platelet-activating factor; PAF, platelet-activating factor; PAF-AH, platelet-activating factor 1327 
acetylhydrolase. 1328 
 1329 
Figure 3: A schematic of the key biological events surrounding PAF-induced inflammation in 1330 
the tumor microenvironment, angiogenesis, and metastasis. These biological events are 1331 
inextricably linked and exacerbate in inflammatory conditions. aFGF, acidic fibroblast growth 1332 
factor; bFGF, basic fibroblast growth factor; COX-2, cyclooxygenase-2; HGF, hepatocyte 1333 
growth factor; ICAM-1, intercellular adhesion molecule-1; IGF-1, insulin-like growth factor 1334 
1; iNOS, inducible nitric oxide synthase; MCP-1, monocyte chemoattractant protein-1 ; MIP-1335 
1α, macrophage inflammatory protein; MMPs, matrix metalloproteinases; PAF, platelet-1336 
activating factor; PAF-R, platelet-activating factor-receptor; PDGE, platelet-derived growth 1337 
factor; ROS, reactive oxygen species; RNS, reactive nitrogen species; VCAM, vascular call 1338 
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